Coherus Biosciences announced plans Friday to acquire Surface Oncology, a clinical-stage immuno-oncology company, in a deal worth up to $65 million. The acquisition aims to bolster Coherus’ position in cancer therapeutics and expand its product portfolio.
Tag Archive for: Yusimry
Coherus BioSciences Inc. said on Thursday it plans to launch a biosimilar of AbbVie Inc’s (ABBV.N) Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug.